Therapeutic Response

Wild type ALK and Wild type EGFR status confers therapeutic sensitivity to Carboplatin in combination with Durvalumab and Tremelimumab in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Imfinzi (durvalumab) [product monograph]. HC. Health Canada approved durvalumab in combination with tremelimumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.